Korea CDC Promoted To Independent Infectious Disease 'Control Tower' Amid COVID-19
Policy And Research Role Redefined
In the midst of the ongoing COVID-19 pandemic, Korea promotes its Centers For Disease Control & Prevention to a central administrative agency that will act as an infectious disease "control tower" that independently carries out investigation and research and sets infectious disease policy. A dedicated vice-minister of health and welfare has also been appointed to step up the public health and medical system.
You may also be interested in...
Cancer deals involving Junshi/Wigen, Allist/Octimet, Yufan/Abound, Takeda/Presage, Daiichi Sankyo/AnHeart, LegoChem/Harbour Biomed, plus a stem cell partnership and a lysosomal storage disorder agreement.
NASH has become a major therapeutic focus for pharma firms in South Korea, where companies are speeding up development and expanding their pipelines after Yuhan’s sizable global license deals last year.
With recently secured platform technology and various programs now entering clinical trials, South Korean RNAi therapeutics company OliX Pharmaceuticals is hoping to reach multiple licensing deals by next year.